Oramed Pharmaceuticals Inc. (ORMP) Stock Forecast & Price Target
Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 12, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Oramed Pharmaceuticals Inc. (ORMP), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Oramed Pharmaceuticals Inc., analysts forecast revenue falling from $2.77M in 2022 to $778,593 in 2027; the average estimate for 2027 earnings per share is −$0.82; 2 analysts contribute to these figures. These are forecasts published by analysts, not results.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Oramed Pharmaceuticals Inc. (ORMP) forecast — frequently asked questions
What are analysts forecasting for Oramed Pharmaceuticals Inc.'s earnings?
The average analyst estimate for Oramed Pharmaceuticals Inc. (ORMP) earnings per share in 2027 is -0.82, with individual estimates between -0.82 and -0.82.
How much revenue is Oramed Pharmaceuticals Inc. expected to make?
Analysts forecast Oramed Pharmaceuticals Inc. (ORMP) revenue of $778,593 in 2027, based on 1 published estimates.
How many analysts cover ORMP?
2 analysts contribute estimates for Oramed Pharmaceuticals Inc. (ORMP). Thin coverage makes an average less reliable.
Analyst forecasts for other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.